Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort

Authors

Sandrine Sourdet (ORCID: https://orcid.org/0000-0001-8967-8915)
Federico Bellelli
Davide Angioni (ORCID: https://orcid.org/0000-0002-8825-7817)
Alberta Peluso
Gabor Abellan van Kan
Bruno Vellas
Gaëlle Soriano

Institutions

Université Toulouse III - Paul Sabatier (FR)
Inserm (FR)
Université Fédérale de Toulouse Midi-Pyrénées (FR)
Centre Hospitalier Universitaire de Toulouse (FR)
Centre de Recherches en Cancérologie de Toulouse (FR)
Federico II University Hospital (IT)
Hôpital de La Grave (FR)

Publication Details

Journal: Alzheimer s Research & Therapy
Published: 2026-02-04
DOI: https://doi.org/10.1186/s13195-026-01966-0
Primary Topic: Health Systems, Economic Evaluations, Quality of Life
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Biogen
Eisai
Novo Nordisk
Genentech
UCB Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort

Sandrine Sourdet, Federico Bellelli, Davide Angioni, Alberta Peluso et al.

Feb 4, 2026

Alzheimer s Research & Therapy

Health Systems, Economic Evaluations, Quality of Life

article

Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort

Sandrine Sourdet, Federico Bellelli, Davide Angioni, Alberta Peluso, Gabor Abellan van Kan, Bruno Vellas, Gaëlle Soriano

February 4, 2026article en

Abstract

No abstract available for this paper.

Alzheimer s Research & TherapyVol. 18(1)

Université Toulouse III - Paul Sabatier (FR), Inserm (FR), Université Fédérale de Toulouse Midi-Pyrénées (FR), Centre Hospitalier Universitaire de Toulouse (FR), Centre de Recherches en Cancérologie de Toulouse (FR), Federico II University Hospital (IT), Hôpital de La Grave (FR)

Biogen, Eisai, Novo Nordisk, Genentech, UCB Pharma

Quality Education

Openalex Percentile: Top 72%

Health Systems, Economic Evaluations, Quality of Life

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.